U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H18O2
Molecular Weight 206.2813
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IBUPROFEN

SMILES

CC(C)Cc1ccc(cc1)C(C)C(=O)O

InChI

InChIKey=HEFNNWSXXWATRW-UHFFFAOYSA-N
InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)

HIDE SMILES / InChI

Molecular Formula C13H18O2
Molecular Weight 206.2813
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20718179

Ibuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-inflammatory drug (NSAID), with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, which are thought to act through inhibition of prostaglandin synthesis. It’s used temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps and temporarily reduces fever. The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more pharmacologically active enantiomer.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

5.8717438E11
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

5.8717438E11
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

5.8717438E11
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

5.8717438E11
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

5.8717438E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
27.9 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBUPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
103 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBUPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.2 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBUPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
IBUPROFEN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Other AEs: Cardiovascular collapse, Acidosis...
Other AEs:
Cardiovascular collapse (grade 5, 1 patient)
Acidosis (grade 5, 1 patient)
Hypothermia (grade 5, 1 patient)
Sources:
90 g single, oral
Overdose
Dose: 90 g
Route: oral
Route: single
Dose: 90 g
Sources:
unknown, 19 years
Health Status: unknown
Age Group: 19 years
Sex: M
Sources:
Other AEs: Polyuria, Acidosis...
Other AEs:
Polyuria (1 patient)
Acidosis (1 patient)
Sources:
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Other AEs: Acute respiratory distress syndrome, Tachypnea...
Other AEs:
Acute respiratory distress syndrome (serious, 1 patient)
Tachypnea (serious, 1 patient)
Septic shock (serious, 1 patient)
Breathlessness (serious, 1 patient)
Septicemia (serious, 1 patient)
Sources:
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources: Page: p.87
unhealthy, 42 years (range: 17-73 years)
n = 195
Health Status: unhealthy
Age Group: 42 years (range: 17-73 years)
Sex: M+F
Population Size: 195
Sources: Page: p.87
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (2%)
Headache (1 patient)
Sources: Page: p.87
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources: Page: p.87
unhealthy, 44 years (range: 20-69 years)
n = 304
Health Status: unhealthy
Age Group: 44 years (range: 20-69 years)
Sex: M+F
Population Size: 304
Sources: Page: p.87
Disc. AE: Headache...
AEs leading to
discontinuation/dose reduction:
Headache (2 patients)
Sources: Page: p.87
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Co-administed with::
divalproex sodium
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Other AEs: Cardiovascular collapse...
Other AEs:
Cardiovascular collapse (grade 5, 1 patient)
Sources:
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Other AEs: Acidosis, Hypothermia...
Other AEs:
Acidosis (grade 5, 1 patient)
Hypothermia (grade 5, 1 patient)
Sources:
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Pain
Age Group: adult
Sources:
Other AEs: Myocardial infarction, Stroke...
Other AEs:
Myocardial infarction (serious|grade 5)
Stroke (serious|grade 5)
Sources:
400 mg 6 times / day multiple, oral
Recommended
Dose: 400 mg, 6 times / day
Route: oral
Route: multiple
Dose: 400 mg, 6 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
Other AEs: Myocardial infarction, Stroke...
Other AEs:
Myocardial infarction (serious|grade 5)
Stroke (serious|grade 5)
Sources:
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Other AEs: Depression, Insomnia...
Other AEs:
Depression (below serious, 1 patient)
Insomnia (below serious, 1 patient)
Oropharyngeal pain (below serious, 1 patient)
Sinus congestion (below serious, 1 patient)
Sources:
97.5 mg 4 times / day multiple, oral
Dose: 97.5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 97.5 mg, 4 times / day
Sources:
unhealthy
n = 112
Health Status: unhealthy
Condition: Dental Pain
Population Size: 112
Sources:
Other AEs: Facial swelling...
Other AEs:
Facial swelling (below serious, 8 patients)
Sources:
10 mg/kg single, oral
Dose: 10 mg/kg
Route: oral
Route: single
Dose: 10 mg/kg
Sources:
unhealthy
n = 29
Health Status: unhealthy
Condition: Post-ERCP Pancreatitis
Population Size: 29
Sources:
Other AEs: Bleeding, Perforation...
Other AEs:
Bleeding (below serious, 2 patients)
Perforation (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Acidosis grade 5, 1 patient
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Cardiovascular collapse grade 5, 1 patient
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Hypothermia grade 5, 1 patient
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Acidosis 1 patient
90 g single, oral
Overdose
Dose: 90 g
Route: oral
Route: single
Dose: 90 g
Sources:
unknown, 19 years
Health Status: unknown
Age Group: 19 years
Sex: M
Sources:
Polyuria 1 patient
90 g single, oral
Overdose
Dose: 90 g
Route: oral
Route: single
Dose: 90 g
Sources:
unknown, 19 years
Health Status: unknown
Age Group: 19 years
Sex: M
Sources:
Acute respiratory distress syndrome serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Breathlessness serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Septic shock serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Septicemia serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Tachypnea serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Headache 1 patient
Disc. AE
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources: Page: p.87
unhealthy, 42 years (range: 17-73 years)
n = 195
Health Status: unhealthy
Age Group: 42 years (range: 17-73 years)
Sex: M+F
Population Size: 195
Sources: Page: p.87
Dizziness 2%
Disc. AE
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources: Page: p.87
unhealthy, 42 years (range: 17-73 years)
n = 195
Health Status: unhealthy
Age Group: 42 years (range: 17-73 years)
Sex: M+F
Population Size: 195
Sources: Page: p.87
Headache 2 patients
Disc. AE
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources: Page: p.87
unhealthy, 44 years (range: 20-69 years)
n = 304
Health Status: unhealthy
Age Group: 44 years (range: 20-69 years)
Sex: M+F
Population Size: 304
Sources: Page: p.87
Cardiovascular collapse grade 5, 1 patient
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Co-administed with::
divalproex sodium
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Acidosis grade 5, 1 patient
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Hypothermia grade 5, 1 patient
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Myocardial infarction serious|grade 5
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Pain
Age Group: adult
Sources:
Stroke serious|grade 5
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Pain
Age Group: adult
Sources:
Myocardial infarction serious|grade 5
400 mg 6 times / day multiple, oral
Recommended
Dose: 400 mg, 6 times / day
Route: oral
Route: multiple
Dose: 400 mg, 6 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
Stroke serious|grade 5
400 mg 6 times / day multiple, oral
Recommended
Dose: 400 mg, 6 times / day
Route: oral
Route: multiple
Dose: 400 mg, 6 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
Depression below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Insomnia below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Oropharyngeal pain below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Sinus congestion below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Facial swelling below serious, 8 patients
97.5 mg 4 times / day multiple, oral
Dose: 97.5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 97.5 mg, 4 times / day
Sources:
unhealthy
n = 112
Health Status: unhealthy
Condition: Dental Pain
Population Size: 112
Sources:
Perforation below serious, 1 patient
10 mg/kg single, oral
Dose: 10 mg/kg
Route: oral
Route: single
Dose: 10 mg/kg
Sources:
unhealthy
n = 29
Health Status: unhealthy
Condition: Post-ERCP Pancreatitis
Population Size: 29
Sources:
Bleeding below serious, 2 patients
10 mg/kg single, oral
Dose: 10 mg/kg
Route: oral
Route: single
Dose: 10 mg/kg
Sources:
unhealthy
n = 29
Health Status: unhealthy
Condition: Post-ERCP Pancreatitis
Population Size: 29
Sources:
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
minor
minor
minor
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.
2001
Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death.
2001
Interpolymer complexation. II. Entrapment of ibuprofen by in-situ complexation between polyvinyl acetate phthalate (PVAP) and polyvinylpyrrolidone (PVP) and development of a chewable tablet formulation.
2001
A benefit/risk analysis of the prevention of brain ischaemia with anticoagulant drugs: when, how and whom to treat?
2001
[Misuse of drugs in recreational sports].
2001 Apr
Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
2001 Apr
Obsessive-compulsive disorder: a neuronal membrane phospholipid hypothesis and concomitant therapeutic strategy.
2001 Apr
Group B Streptococci and inducible nitric oxide synthase: modulation by nuclear factor kappa B and ibuprofen.
2001 Apr
Ibuprofen-lysine for closure of patent ductus arteriosus.
2001 Apr
In vitro effect of different non-steroidal anti-inflammatory drugs on human polymorphonuclear leukocyte activity measured by luminol-dependent chemiluminescence of the whole blood.
2001 Apr
Ibuprofen-induced bullous leukocytoclastic vasculitis.
2001 Apr
Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
2001 Apr
Induced accumulation of 2-hydroxy-4,7-dimethoxy-1,4-benzoxazin-3-one glucoside (HDMBOA-Glc) in maize leaves.
2001 Apr
Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen.
2001 Apr
Nonsurgical female sterilization: comparison of intrauterine application of quinacrine alone or in combination with ibuprofen.
2001 Apr
Percutaneous, intramuscular neuromuscular electrical stimulation for the treatment of shoulder subluxation and pain in chronic hemiplegia: a case report.
2001 Apr
The effect of standard care, ibuprofen, and music on pain relief and patient satisfaction in adults with musculoskeletal trauma.
2001 Apr
Esophageal laceration and charcoal mediastinum complicating gastric lavage.
2001 Apr
Permeability of endothelial monolayers to albumin is increased by bradykinin and inhibited by prostaglandins.
2001 Apr
Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention.
2001 Apr 15
IL-10 mediation of activation-induced TH1 cell apoptosis and lymphoid dysfunction in polymicrobial sepsis.
2001 Apr 7
Investigational COX-2 inhibitor relieves pain in dental model.
2001 Feb
Determination of nonsteroidal anti-inflammatory drugs in biological fluids by automatic on-line integration of solid-phase extraction and capillary electrophoresis.
2001 Feb
Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry.
2001 Feb 23
Activity profile of glycolamide ester prodrugs of ibuprofen.
2001 Jan
Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay.
2001 Jan-Apr
Investigation of foreign substances in food.
2001 Jan-Feb
[Necrotizing fasciitis. Clinical criteria and risk factors].
2001 Mar
Synthesis of N-pyridinyl(methyl)-1,2-dihydro-4-hydroxy-2-oxoquinoline-3-carboxamides and analogues and their anti-inflammatory activity in mice and rats.
2001 Mar
Synthesis and hydrolytic behaviour of glycerol-1,2-diibuprofenate-3-nitrate, a putative pro-drug of ibuprofen and glycerol-1-nitrate.
2001 Mar
Inhibitors of arachidonic acid metabolism have variable effects on calcium signaling pathways.
2001 Mar
Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis.
2001 Mar
Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals.
2001 Mar
Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms.
2001 Mar
Audit of pain management at home following tonsillectomy in children.
2001 Mar
Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough?
2001 Mar
Continuous low-level topical heat in the treatment of dysmenorrhea.
2001 Mar
NSAIDs bound to methacrylic carriers: microstructural characterization and in vitro release analysis.
2001 Mar 12
Expression of rat liver long-chain acyl-CoA synthetase and characterization of its role in the metabolism of R-ibuprofen and other fatty acid-like xenobiotics.
2001 Mar 15
Simultaneous quantification of neutral and acidic pharmaceuticals and pesticides at the low-ng/l level in surface and waste water.
2001 Mar 16
Use of glucosamine and chondroitin sulfate in the management of osteoarthritis.
2001 Mar-Apr
Linear drug eruption.
2001 Mar-Apr
Coexisting linear and disseminated drug eruption: a clinical clue to the understanding of the genetic basis of drug eruptions.
2001 Mar-Apr
Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella.
2001 May
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
2001 May
Indomethacin and telomerase activity in tumor growth retardation.
2001 May
Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations.
2001 May 1
Chemical reactivity in solid-state pharmaceuticals: formulation implications.
2001 May 16
Microencapsulation of ibuprofen and Eudragit RS 100 by the emulsion solvent diffusion technique.
2001 May 7
Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women.
2001 May-Jun
Patents

Sample Use Guides

adults: take 1 tablet every 4 to 6 hours while symptoms persist. If pain or fever does not respond to 1 tablet, 2 tablets may be used; do not exceed 6 tablets in 24 hours. Children under 12 years: ask a doctor.
Route of Administration: Oral
Ibuprofen, in a 400-μM concentration, decreased the expression of Hsp70 by 23% in comparison with untreated cells, whereas other NSAID had no effect. Ibuprofen also decreased the expression of Hsp70 in H358, a human lung adenocarcinoma cell line, in a dose-dependent manner (from 0-400 uM).
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:54:23 UTC 2021
Edited
by admin
on Fri Jun 25 20:54:23 UTC 2021
Record UNII
WK2XYI10QM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IBUPROFEN
EMA EPAR   EP   HSDB   INCI   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   INCI   USAN  
Official Name English
IBUPROFEN COMPONENT OF ADVIL ALLERGY SINUS
Common Name English
IB-100
Code English
IBUPROFEN COMPONENT OF SINE-AID IB
Common Name English
IBUPROFEN COMPONENT OF CHILDREN'S MOTRIN COLD
Common Name English
IBUPROFEN [INN]
Common Name English
U-18,573
Code English
IBUPROFEN COMPONENT OF VICOPROFEN
Common Name English
PROFEN
Brand Name English
IBUPROFEN [EP MONOGRAPH]
Common Name English
(+/-)-2-(P-ISOBUTYLPHENYL)PROPIONIC ACID
Common Name English
CAP-PROFEN
Brand Name English
IBUPROFEN [MI]
Common Name English
IBUPROFEN [ORANGE BOOK]
Common Name English
IBUPROFEN COMPONENT OF REPREXAIN
Common Name English
IBUPROFEN [EMA EPAR]
Common Name English
(+/-)-P-ISOBUTYLHYDRATROPIC ACID
Common Name English
TAB-PROFEN
Brand Name English
VICOPROFEN COMPONENT IBUPROFEN
Common Name English
IBUPROFEN [HSDB]
Common Name English
IBUPROFEN [USP-RS]
Common Name English
NSC-256857
Code English
BENZENEACETIC ACID, .ALPHA.-METHYL-4-(2-METHYLPROPYL), (+/-)-
Common Name English
ADVIL ALLERGY SINUS COMPONENT IBUPROFEN
Common Name English
IBUPROFEN [INCI]
Common Name English
IBU-TAB
Brand Name English
CALDOLOR
Brand Name English
BURANA
Brand Name English
IBUPROFEN [MART.]
Common Name English
NUPRIN
Brand Name English
ADVIL CONGESTION RELIEF COMPONENT IBUPROFEN
Common Name English
ACHES-N-PAIN
Brand Name English
IBUPROFEN COMPONENT OF COMBUNOX
Common Name English
IBUPROFEN [USP MONOGRAPH]
Common Name English
MIDOL
Brand Name English
IBUPROFEN [WHO-DD]
Common Name English
IBUPROFEN COMPONENT OF CHILDREN'S ADVIL COLD
Common Name English
BENZENEACETIC ACID, .ALPHA.-METHYL-4-(2-METHYLPROPYL)-
Common Name English
M01AE01
Code English
(+/-)-IBUPROFEN
Common Name English
CHILDREN'S ADVIL COLD COMPONENT IBUPROFEN
Common Name English
IBUPROFEN COMPONENT OF ADVIL CONGESTION RELIEF
Common Name English
U-18573
Code English
COMBUNOX COMPONENT IBUPROFEN
Common Name English
REPREXAIN COMPONENT IBUPROFEN
Common Name English
RD 13621
Code English
IBUPRIN
Brand Name English
MEDIPREN
Brand Name English
RUFEN
Brand Name English
PEDEA
Brand Name English
IBUPROFEN [USAN]
Common Name English
IBUPROFEN [USP]
Common Name English
IBUPROFEN [WHO-IP]
Common Name English
IBUPROFEN [VANDF]
Common Name English
MOTRIN
Brand Name English
IBU
Brand Name English
SINE-AID IB COMPONENT IBUPROFEN
Common Name English
IBUPROFENUM [WHO-IP LATIN]
Common Name English
CHILDREN'S MOTRIN COLD COMPONENT IBUPROFEN
Common Name English
IBUPROHM
Brand Name English
ADVIL
Brand Name English
Classification Tree Code System Code
WHO-ATC N02AJ19
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
LIVERTOX 495
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
NDF-RT N0000000160
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
WHO-VATC QM02AA13
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
WHO-ATC G02CC01
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 7.1
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
FDA ORPHAN DRUG 100896
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.4
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
WHO-ATC M01AE51
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
NDF-RT N0000175721
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
EU-Orphan Drug EU/3/01/020
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
WHO-VATC QM01AE51
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
WHO-VATC QM01AE01
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
WHO-VATC QG02CC01
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
NDF-RT N0000175722
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
NCI_THESAURUS C1323
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
WHO-ATC R02AX02
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
WHO-ATC M01AE01
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
WHO-ATC N02AJ08
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
WHO-ATC C01EB16
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
EMA ASSESSMENT REPORTS PEDEA (AUTHORIZED: DUCTUS ATERIOSUS, PATENT)
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 29
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 2.1
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
WHO-ATC M02AA13
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
WHO-VATC QC01EB16
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
Code System Code Type Description
MERCK INDEX
M6189
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL521
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
NCI_THESAURUS
C561
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
FDA UNII
WK2XYI10QM
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
CAS
15687-27-1
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
MESH
D007052
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
CAS
58560-75-1
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
SUPERSEDED
DRUG BANK
DB01050
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
INN
2118
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
DRUG CENTRAL
1407
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
RXCUI
5640
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
PRIMARY RxNorm
IUPHAR
2713
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
ECHA (EC/EINECS)
239-784-6
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
CAS
139466-08-3
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
SUPERSEDED
EPA CompTox
15687-27-1
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
HSDB
3099
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
IBUPROFEN
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
PRIMARY Description: Colourless crystals or a white, crystalline powder; odour, characteristic. Solubility: Practically insoluble in water; soluble in 1.5 parts of ethanol (~750 g/l) TS, in 2 parts of ether R and in 1.5 parts of acetone R. Category: Analgesic; anti-inflammatory. Storage: Ibuprofen should be kept in a well-closed container. Definition: Ibuprofen contains not less than 98.5% and not more than 100.5% of C13H18O2, calculated with reference to the dried substance.
PUBCHEM
3672
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
PRIMARY
USP_CATALOG
1335508
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
PRIMARY USP-RS
LACTMED
Ibuprofen
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
WIKIPEDIA
IBUPROFEN
Created by admin on Fri Jun 25 20:54:25 UTC 2021 , Edited by admin on Fri Jun 25 20:54:25 UTC 2021
PRIMARY
EVMPD
SUB08098MIG
Created by admin on Fri Jun 25 20:54:24 UTC 2021 , Edited by admin on Fri Jun 25 20:54:24 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE INACTIVE -> PARENT
MINOR
METABOLITE INACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
MAJOR
URINE
METABOLITE INACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
MAJOR
URINE
METABOLITE INACTIVE -> PARENT
MINOR
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MAXIMUM TOLERATED DOSE PHARMACOKINETIC INDICATION
BIOLOGICAL
ROUTE OF ADMINSTRATION
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC PEDIATRICS
PHARMACOKINETIC
Cmax PHARMACOKINETIC ROUTE OF ADMINSTRATION

DOSE
PHARMACOKINETIC
Tmax PHARMACOKINETIC FOOD EFFECT
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC